2021 Annual Meeting: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational I

2021 Annual Meeting: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Genomics

2021 Annual Meeting: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Immunology

2021 Annual Meeting: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Myeloma pathogenesis and novel targets

2021 Annual Meeting: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: The Myeloma Immune Microenvironment

2021 Annual Meeting: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: A Map for the Changing Landscape of Multiple Myeloma

2021 Annual Meeting: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Challenges in Multiple Myeloma Therapy: Adopting New Approaches for Relapse and Monitor

2021 Annual Meeting: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Monoclonal Gammopathies of Determined Significance: What We Have and What We Want

2021 Annual Meeting: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Multiple Myeloma and Waldenstrom Macroglobulinemia: Exploring Biomarkers in the Era of Personalized Medicine

2021 Annual Meeting: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Reoptimizing Standards and Redefining Approaches

2021 Annual Meeting: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials; treatment of NDMM and amyloidosis patients

2021 Annual Meeting: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Immune Therapy for Multiple Myeloma

2021 Annual Meeting: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Novel Targets and Amyloid

2021 Annual Meeting: 653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Phase 2 and 3 Trials in Myeloma

2021 Annual Meeting: 701. Experimental Transplantation: Basic and Translational: Molecular Mediators of Post-transplant GVHD, Relapse and Immune Reconstitution

2021 Annual Meeting: 701. Experimental Transplantation: Basic and Translational: The GI Tract and GVHD: Modeling the Structural and Microbial Elements of Disease

2021 Annual Meeting: 703. Cellular Immunotherapies: Basic and Translational I

2021 Annual Meeting: 703. Cellular Immunotherapies: Basic and Translational II

2021 Annual Meeting: 703. Cellular Immunotherapies: Basic and Translational III

2021 Annual Meeting: 703. Cellular Immunotherapies: Basic and Translational IV

2021 Annual Meeting: 704. Cellular Immunotherapies: Allogeneic CARs and CARs for T Cell Lymphomas

2021 Annual Meeting: 704. Cellular Immunotherapies: Cellular Therapies for ALL

2021 Annual Meeting: 704. Cellular Immunotherapies: Cellular Therapies for Low and High Grade Lymphomas

2021 Annual Meeting: 704. Cellular Immunotherapies: Cellular Therapies for Lymphomas

2021 Annual Meeting: 704. Cellular Immunotherapies: Cellular Therapies for Myeloma

2021 Annual Meeting: 704. Cellular Immunotherapies: Cellular Therapies-Immune Interactions, Lineage Switching and CNS targets

2021 Annual Meeting: 711. Cell Collection and Processing: Advances in Mobilization, Collection, Manipulation and Engineering of HSCs and T Cells

2021 Annual Meeting: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities; Novel Conditioning Approaches.

2021 Annual Meeting: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities; Potential Factors Affecting Outcomes of Variable Transplant Settings.

2021 Annual Meeting: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities; Prevention and Management of Complications.